|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2005-6-20
|
|
pubmed:abstractText |
The genetically polymorphic cytochrome P450 (CYP) enzyme CYP2C9 metabolizes most sulphonylurea oral hypoglycaemic agents. The aim of this study was to test the hypothesis that individuals with genotypes predicting low CYP2C9 activity may be at a higher risk of severe drug-associated hypoglycaemia.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0306-5251
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
103-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15963101-Aged,
pubmed-meshheading:15963101-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:15963101-Case-Control Studies,
pubmed-meshheading:15963101-Diabetes Mellitus, Type 2,
pubmed-meshheading:15963101-Genotype,
pubmed-meshheading:15963101-Glyburide,
pubmed-meshheading:15963101-Humans,
pubmed-meshheading:15963101-Hypoglycemia,
pubmed-meshheading:15963101-Hypoglycemic Agents,
pubmed-meshheading:15963101-Sulfonylurea Compounds
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
|
|
pubmed:affiliation |
1st Department of Medicine, Klinikum Lippe, Detmold, Germany.
|
|
pubmed:publicationType |
Journal Article
|
